Investors
We are transforming the science of medical imaging, creating a new world of possibilities for the biopharmaceutical industry and healthcare professionals alike. By accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.
We deliver on a global scale. Our reach stretches worldwide, from the USA, the world’s largest healthcare market, across Europe, and into Asia, an increasingly important region for clinical development and patient care. This global presence is reflected by our work with world-leading pharmaceutical and biotechnology companies and contract research organizations. The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.
Board of directors and management team
Experienced leadership
Median’s management team has extensive experience of the imaging, patient care and clinical trial sectors. Our Board of Directors brings significant industry, financial and strategic expertise to the company.
Major shareholders
Stock market data
Median Technologies is listed on Euronext Growth
(ISIN: FR0011049824, ticker: ALMDT)
Stock market data
Place of listing
Euronext Growth
Number of shares
12,138,425
(December 31, 2020)
Share code
Name
Median Technologies
Mnemonic
ALMDT
ISIN Code
FR0011049824
Shareholding structure (December 31, 2020)
- FURUI Medical Science Company Luxembourg: 12.42%
- Celestial Successor Fund LP: 10.75%
- Abingworth LLP (nominative and non nominative): 9.15%
- Canon Inc: 7.92%
- Founders - Management - Employees: 7.63%
- Auriga Ventures II (nominative and non nominative): 5.01%
- Others (including Topeka - Polar Capital - NEA - Idinvest): 47.11%
Financial agenda
- 2021
- Publication of our annual results 2020: after the close of trading on April 8, 2021
- 2020
- Publication of our half-year results 2020: after the close of trading on October 14, 2020
- Publication of our annual results 2019: after the close of trading on April 14, 2020
- 2019
- Publication of our half-year results 2019: after the close of trading on October 3, 2019
- Publication of our annual results for 2018: after the close of trading on April 11, 2019
- 2018
- Publication of our half-year results 2018: after the close of trading on October 11, 2018
- Publication of our annual results for 2017: after the close of trading on April 12, 2018
- 2017
- Publication of our half-year results 2017: after the close of trading on October 10, 2017
- Publication of our annual results for 2016: after the close of trading on April 12, 2017
- 2016
- Publication of our half-year results 2016: after the close of trading on October 12, 2016
- Publication of our annual results for 2015: after the close of trading on April 12, 2016
- 2015
- Publication of our half-year results 2015: after the close of trading on October 5, 2015
- Publication of our annual results for 2014: after the close of trading on April 15, 2015
- 2014
- Publication of our half-year results 2014: after the close of trading on October 9, 2014
- Publication of our annual results for 2013: after the close of trading on April 28, 2014
- 2013
- Publication of our half-year results 2013: after the close of trading on October 10, 2013
- Publication of our annual results for 2012: after the close of trading on April 10, 2013
- 2012
- Publication of our half-year results 2012: after the close of trading on October 8, 2012
- Publication of our annual results for 2011: after the close of trading on February 16, 2012
- 2011
- Publication of our half-year results 2011: after the close of trading on September 16, 2011
Press releases and documentation
Investor contacts
Actifin – Communication financière
Ghislaine Gasparetto
Tel: +33 1 56 88 11 11
